General Information of Drug (ID: DMG9B1U)

Drug Name
Elvitegravir
Synonyms EVG
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 447.9
Logarithm of the Partition Coefficient (xlogp) 5.3
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 8.7 hours [2]
Metabolism
The drug is metabolized via the CYP3A, and is secondarily glucuronidated via UGT1A1/3 enzymes []
Chemical Identifiers
Formula
C23H23ClFNO5
IUPAC Name
6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid
Canonical SMILES
CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O
InChI
InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1
InChIKey
JUZYLCPPVHEVSV-LJQANCHMSA-N
Cross-matching ID
PubChem CID
5277135
ChEBI ID
CHEBI:72289
CAS Number
697761-98-1
DrugBank ID
DB09101
TTD ID
D0QD1G
INTEDE ID
DR0570
ACDINA ID
D00227
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Integrase (HIV IN) TT5FH9Y POL_HV1B1 Modulator [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME
DE4LYSA CP3A4_HUMAN Substrate [3]
UDP-glucuronosyltransferase 1A1 (UGT1A1)
Main DME
DEYGVN4 UD11_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Elvitegravir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Elvitegravir caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [5]
Arn-509 DMT81LZ Major Increased metabolism of Elvitegravir caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [6]
Erdafitinib DMI782S Major Increased metabolism of Elvitegravir caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [7]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Elvitegravir caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [5]
Lumacaftor DMCLWDJ Major Increased metabolism of Elvitegravir caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [6]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Elvitegravir caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [5]
PF-06463922 DMKM7EW Moderate Increased metabolism of Elvitegravir caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [5]
Elagolix DMB2C0E Moderate Increased metabolism of Elvitegravir caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [5]
⏷ Show the Full List of 8 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Elvitegravir 150 mg tablet 150 mg Oral Tablet Oral
Elvitegravir 85 mg tablet 85 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 FDA Label of Elvitegravir. The 2020 official website of the U.S. Food and Drug Administration.
4 Elvitegravir for the treatment of HIV infection. Drugs Today (Barc). 2014 Mar;50(3):209-17.
5 Cerner Multum, Inc. "Australian Product Information.".
6 Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
7 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.